NFE2L1-DT

Across TCGA pan-cancer cohorts, NFE2L1-DT RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of NFE2L1-DT’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where NFE2L1-DT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types NFE2L1-DT is over-expressed in tumor, although a few such as KICH show the opposite, repressed pattern.

HNSC, LIHC, and COAD are the cancer types where NFE2L1-DT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NFE2L1-DT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.255	<.001	10	view →
LIHC	Male	II,III,IV	+0.466	<.001	9	view →
COAD	Male	II,III,IV	+0.367	<.001	9	view →
LUSC	Male	II,III,IV	+0.509	<.001	6	view →
BLCA	All	All	+0.336	<.001	6	view →
BRCA	Female	II,III,IV	+0.170	.004	6	view →
KICH	Male	All	−0.500	<.001	5	view →
LUAD	All	All	+0.291	<.001	5	view →
STAD	All	All	+0.166	.006	4	view →
CHOL	All	All	+0.736	<.001	3	view →
KIRP	All	II,III,IV	+0.357	.015	3	view →
PRAD	All	All	+0.107	.038	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

NFE2L1-DT–HNSC

Open the HNSC breakdown →